Free Trial
NASDAQ:CALC

CalciMedica (CALC) Stock Price, News & Analysis

CalciMedica logo
$2.00 -0.06 (-2.91%)
As of 03:59 PM Eastern

About CalciMedica Stock (NASDAQ:CALC)

Key Stats

Today's Range
$1.97
$2.03
50-Day Range
$1.48
$2.27
52-Week Range
$1.43
$6.02
Volume
13,748 shs
Average Volume
45,167 shs
Market Capitalization
$27.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
Consensus Rating
Buy

Company Overview

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

CalciMedica Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

CALC MarketRank™: 

CalciMedica scored higher than 35% of companies evaluated by MarketBeat, and ranked 721st out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CalciMedica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CalciMedica has only been the subject of 1 research reports in the past 90 days.

  • Read more about CalciMedica's stock forecast and price target.
  • Earnings Growth

    Earnings for CalciMedica are expected to decrease in the coming year, from ($2.21) to ($2.24) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CalciMedica is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CalciMedica is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CalciMedica has a P/B Ratio of 1.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about CalciMedica's valuation and earnings.
  • Percentage of Shares Shorted

    1.75% of the float of CalciMedica has been sold short.
  • Short Interest Ratio / Days to Cover

    CalciMedica has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CalciMedica has recently decreased by 1.91%, indicating that investor sentiment is improving.
  • Dividend Yield

    CalciMedica does not currently pay a dividend.

  • Dividend Growth

    CalciMedica does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.75% of the float of CalciMedica has been sold short.
  • Short Interest Ratio / Days to Cover

    CalciMedica has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CalciMedica has recently decreased by 1.91%, indicating that investor sentiment is improving.
  • Search Interest

    Only 1 people have searched for CALC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CalciMedica insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    41.55% of the stock of CalciMedica is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about CalciMedica's insider trading history.
Receive CALC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CalciMedica and its competitors with MarketBeat's FREE daily newsletter.

CALC Stock News Headlines

Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
CalciMedica Inc. Common Stock
See More Headlines

CALC Stock Analysis - Frequently Asked Questions

CalciMedica's stock was trading at $3.54 at the beginning of 2025. Since then, CALC shares have decreased by 43.2% and is now trading at $2.01.
View the best growth stocks for 2025 here
.

CalciMedica, Inc. (NASDAQ:CALC) announced its quarterly earnings results on Thursday, March, 27th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.14.

CalciMedica's top institutional shareholders include Cambridge Investment Research Advisors Inc. (0.17%) and 180 Wealth Advisors LLC (0.12%). Insiders that own company stock include Sanderling Venture Partners Vi, Robert N Wilson, Eric W Roberts and A Rachel Leheny.
View institutional ownership trends
.

Shares of CALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CalciMedica investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Castor Maritime (CTRM).

Company Calendar

Last Earnings
3/27/2025
Today
5/09/2025
Next Earnings (Estimated)
5/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CALC
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$20.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+795.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-34,360,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.42 per share
Price / Book
1.42

Miscellaneous

Free Float
7,880,000
Market Cap
$28.08 million
Optionable
No Data
Beta
1.24
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:CALC) was last updated on 5/9/2025 by MarketBeat.com Staff
From Our Partners